Загрузка...
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial
OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-control...
Сохранить в:
| Опубликовано в: : | Obstet Gynecol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7963450/ https://ncbi.nlm.nih.gov/pubmed/30303923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000002933 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|